FLUMIST Research Report 2023: The Most Widely Available Quadrivalent Live Attenuated Influenza Vaccine - Drug Insights and Market Forecasts 2019-2032
12 déc. 2023 05h08 HE
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUMIST QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Seasonal Influenza Vaccines Market Report 2020: Flucelvax QIV and Flublok QIV are Expected to Experience Sales Growth Following Anticipated Regulatory Approvals in the EU in Q4 2020
04 déc. 2020 03h58 HE
|
Research and Markets
Dublin, Dec. 04, 2020 (GLOBE NEWSWIRE) -- The "Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering. The seasonal influenza vaccines market in the US, Japan, and...
US Influenza Vaccines Market Size and Analysis 2020: Clinical Trial Insights by Phase, Company and Country
04 sept. 2020 06h34 HE
|
Research and Markets
Dublin, Sept. 04, 2020 (GLOBE NEWSWIRE) -- The "United States Influenza Vaccines Market Forecast 2020 - 2027" report has been added to ResearchAndMarkets.com's offering. The United States...
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
15 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...
A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference
28 janv. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...
Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season
16 déc. 2013 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new...
FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses
09 déc. 2013 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that its Phase 1/2 clinical trial at the University of Alabama...